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Daily ambulatory exhaled nitric oxide
measurements in asthma
The fraction of nitric oxide in exhaled air
(FENO) correlates with eosinophils in induced
sputum and with eosinophil infiltration of the
airway wall in atopic asthmatics (1–5). This
makes FENO a candidate marker to monitor
asthmatic airway inflammation. In the clinic,
FENO is routinely measured by chemilumines-
cence analyzers, which are expensive, not easily
transportable, require frequent calibration and
thus are not suitable for home monitoring.
Recently, a new hand-held NO-analyzer (NIOX
MINOTM, Aerocrine, Solna, Sweden) was devel-
oped, which offers the possibility to measure
FENO in the home situation. A good agreement
between FENO tests with a conventional,
approved NO-analyzer (NIOX, Aerocrine, Sol-
na, Sweden) and NIOXMINO was observed in a
recent study (6). Home monitoring of FENO has
the potential to detect inflammation at an early
stage and adapt treatment with inhaled steroids
accordingly. This study was performed to evalu-
ate feasibility and variability of FENO measure-
ments with NIOX MINOTM at home. Second,
we investigated the correlation between symp-
toms and FENO during the two weeks of the
study.
Methods
Patients with doctor’s diagnosed asthma, aged
6–25 yr were recruited during their outpatient
clinic visit at the hospital. Patients should be in a
stable clinical condition as judged by their own
pediatric pulmonologist. Patients who had an
exacerbation or used oral prednisone in the
3 months preceding the study, or who used
rescue beta-2 agonists more than four times a
week in the 2 wk preceding the study, patients
who smoked and patients with a concurrent
disease affecting FENO were excluded. Atopy
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Exhaled NO (FENO) is a non-invasive, validated marker for asthmatic
airway inflammation. Recently, a new hand-held NO-analyzer has been
developed which makes it possible to monitor FENO at home. We
assessed feasibility and analyzed variability of daily FENO home
measurements. Twenty-one asthmatics (mean age 14.5 yr; range 8–
25 yr) participated. Nineteen used a stable dose of inhaled corticoster-
oids and all of them were in a stable clinical condition. FENO was
measured twice daily for 14 consecutive days. Measurements and
symptom scores were recorded on a smart card in the analyzer.
Symptom score items included well-being, wheeze, activity, and noc-
turnal symptoms. Measurements showed a success rate of 93%. We
found a significant diurnal variation in FENO with geometric mean
morning levels 14% higher than evening levels (95% CI: 4%–25%; p ¼
0.013). Individual subjects showed marked fluctuation of FENO. The
mean intrasubject coefficient of variation of FENO was 40% for
morning and 36% for evening values. FENO and cumulative symptom
scores did not correlate. Home FENO measurements are feasible, and
offer the possibility to asses airway inflammation on a daily basis.
Further study is needed to interpret and evaluate possible benefits of
FENO home monitoring.
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was defined as RAST class 2 or higher for at least
one inhalation allergen ever. The study was
approved by the Medical Ethical Committee of
the Erasmus University Medical Centre. In an
open, observational, prospective study, patients
measured FENO twice daily for 2 wk at home.
The NIOX MINOTM measures NO by an
electrochemical sensor (Fig. 1). The measure-
ment range is between 0 and 300 ppb with an
accuracy of ±5 ppb or ±10% if FENO is
>30 ppb. Deep inhalation through the mouth-
piece provides NO-free air via an NO-scrubber.
Next, exhalation for 10 s with a constant flow of
50 ml/s is required. A visual and audible feed-
back system helps to maintain pressure within
pre-set limits to ensure constant flow. Measure-
ments are approved if exhaled pressure is
between 10 and 20 cm H2O with deviation
allowed during the first 3 s of the measurement.
For this study, there was no maximum for the
number of allowed attempts. In previous studies
NIOX MINOTM was validated and compared
with the conventional NIOX NO-analyzer and
showed good agreement (6, 7). NIOX MINOTM
is provided with a smart card, which records all
measurement results and time of measurements.
The product we used also has a diary function
where symptom scores can be recorded. Well-
being, wheeze, activity, and nocturnal symptoms
are scored on a 4-point scale (maximal daily
score 12) and entered in an electronic diary. Data
on FENO levels are available within minutes
after the maneuver; symptom scores can be
entered during these minutes. Patients were
instructed by one researcher (SF) and were
provided with a hand-held analyzer in case of
satisfactory performance.
Mixed Model anova was used to compare
morning and evening FENO values and to
investigate the correlation between FENO and
cumulative symptom scores. In these analyses
FENO values were log transformed. Spearman
non-parametric correlation was used to assess the
correlation of age with feasibility. Significance
was assumed at p < 0.05. SPSS for Windows
Version 10.1 and SAS (procedure PROC
MIXED) were used for statistical analyses.
Results
Twenty-one asthmatics (11 males) were included.
Their mean (range) age was 14.5 yr (8.1–25.8), 18
of them were atopic. Lung function measure-
ments showed a mean (range) FEV1 of 93% of
predicted (57%–120%) and a mean FVC of
100% (75%–124%). Nineteen used an inhaled
steroid, median dose (range) 400 lg/day budes-
onide or equivalent (200–1600). Of those, 12 used
a long-acting beta agonist as well.
Of the maximum number of 588 FENO
measurements (21 subjects, twice daily for
2 wk) 44 values were missing, which gives a
success rate of 93%. Non-adherence was the
main cause of missing values. The success rate
was age-dependent, in the way that older age was
associated with worse adherence (r ¼ –0.56, p ¼
0.008). The only technical problem requiring
intervention of the researchers was sensor failure
in one analyzer.
Only three patients were non-atopic and as
atopy might affect variability of FENO and the
correlation with symptoms, these patients were
excluded from further analyses. Two of them
used a combination of inhaled steroids and a
long-acting beta-2 agonist, the other one did not
use any medication. Geometric mean morning
FENO in the remaining 18 patients was 14%
higher compared to evening levels (95% CI: 4%–
25%; p ¼ 0.013) (Fig. 2). There was marked
fluctuation of FENO in individual patients with
a mean coefficient of variation (CV) of 40% for
morning values (range 18%–93%) and 36% for
evening values (range 15–72). The difference in
coefficient of variation for morning and evening
values was not significant (p ¼ 0.35, Wilcoxon
signed ranks test).
Overall, no significant correlation between the
mean daily symptom scores and geometric mean
FENO-levels was found (Fig. 3). In the same
way, within-patients between-days changes of
FENO did not correlate with changes of cumu-
lative symptoms on following days.
Analysis of the results within individuals
showed a number of patterns, of which examples
Fig. 1. Six-year-old patient performing a measurement of
FENO with the NIOX MINOTM.
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are shown in Fig. 4. Most children showed
stable, low FENO with either stable, low-symp-
tom scores (n ¼ 8) (Fig. 4a) or high, sometimes
widely varying symptom scores (n ¼ 7) (Fig. 4b).
Five showed evident parallel changes of FENO
and symptoms over several days: one of them
started measuring immediately upon returning
from a school camp and showed a gradual
normalization of extremely high FENO within
2 wk, paralleled by a reduction in symptoms
(Fig. 4c). Another child visited a similar camp
during the 2 wk of monitoring; afterward both
FENO and symptoms had risen dramatically
(Fig. 4d). One patient showed high stable FENO
with low symptoms (Fig. 4e), and one high stable
FENO with high symptom scores (Fig. 4f).
Discussion
This is the first report on FENO measurements
taken by asthmatic patients in their homes. Until
now, the bulky and complicated NO chemilumi-
nescence analyzers have limited the applicability
of FENO as an instrument for frequent monit-
oring of airway inflammation in asthma. The
new hand-held analyzer was successfully used for
daily home measurements of FENO during 2 wk,
without professional support. We found signifi-
cant diurnal FENO variability with highest
values in the morning, and considerable day-
to-day variation. Mean FENO values and chan-
ges in FENO between days did not correlate with
mean symptom scores within the time frame of
the study; individual results were suggestive
of parallel changes in some children as a result
of external factors.
Others and we have shown that FENO corre-
lates with eosinophilic airway inflammation,
assessed in induced sputum or airway biopsies
in atopic asthmatic adults and children (1–5).
Treatment with corticosteroids reduces FENO
levels in asthmatic patients in a dose-dependent
manner (8, 9). Measuring FENO at home on a
daily basis offers the possibility to detect changes
in inflammation in an early stage and to adjust
treatment accordingly.
We demonstrated a marked diurnal FENO
variation. This is in line with findings by Mattes
et al., who found a statistical trend towards
higher morning FENO values and a cosine like
circadian rhythm of FENO, for asthmatic as well
as a small number of healthy children (10). Ten
Hacken et al. found higher FENO at 4 a.m.
compared to 4 p.m. in adult patients with noc-
turnal asthma and peak flow variability of
>15% (11). In contrast, Kharitonov et al. found
no diurnal or day-to-day variation in healthy and
asthmatic adults and children during a 5-day
follow-up (12). The mechanism of diurnal FENO
variation is still unclear. Both variation in the
inflammatory process and external factors like
sleep and food intake might play a role. For the
moment, it seems important to perform serial
FENO measurements within patients at the same
time of the day.
In the present study, day-to-day variation of
FENO was common, however, especially in the
lower (normal) FENO ranges this variability is
clinically not relevant. Although we tried to
include patients with stable asthma, almost half
of them experienced clinical instability during the
Fig. 2. Individual diurnal variability of geometric mean
FENO for each patient. Morning values (closed symbols)
and afternoon values (open symbols) ±1 s.d. for each
patient during 2 wk. The mean diurnal variation of all pa-
tients was 14% (95% CI 4%–25%, p ¼ 0.013).
Fig. 3. Mean daily cumulative symptom scores (vertical
axis) as a function of geometric mean FENO-levels. Each
symbol represents a patient. The correlation was not signi-
ficant.
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study and in some cases an external trigger
seemed responsible for parallel changes in FENO
and symptoms (Fig. 4). This clinical instability
may at least partly explain the high day-to-day
variation we found in this study. On the con-
trary, some individuals showed marked instabil-
ity of symptoms with stable, low FENO.
There is a good agreement between FENO
measurements with NIOX MINO and a conven-
tional chemiluminescence analyzer. In this study,
an average disagreement of 0.5 ppb with a mean
standard deviation of 3.8 ppb was found from
251 measurements in 19 subjects (6). This makes
it very unlikely that the diurnal variability may
be explained by variability of the analyzer itself.
Our study was not designed to answer the
question if home monitoring of FENO might
predict clinical instability. Earlier studies on the
correlation of FENO and asthma severity and
control show conflicting results. These may be
due to different FENO measuring techniques,
patient selection criteria and the use of ICS
(13–20). However, some recent studies including
our own showed that FENO might be used as a
loss of control marker, predicting asthma exac-
erbations or relapse after cessation or reduction
of ICS (21–23). In the study of Jones, single
measurements and changes of FENO from
baseline had positive predictive values of 80%–
90% for predicting and diagnosing loss of
asthma control (22). In a previous study, we
followed children with clinical remission of
asthma who were taken off ICS; FENO at 2
and 4 wk after withdrawal predicted asthma
relapse in the forthcoming months (23). We
speculate that the lack of a correlation between
symptoms and FENO in the present study may
be due to its limited time frame. The question is
whether FENO might be used to adapt ICS
doses, and whether or not frequent home mon-
itoring has advantages above infrequent assess-
ment at clinic visits. The relevance of FENO
fluctuations for asthma management is clearly
important to elucidate.
We conclude that ambulatory FENO meas-
urements with NIOX MINOTM are feasible, and
offer the possibility to measure asthmatic inflam-
mation frequently at home. Morning values are
significantly higher than evening values and
considerable day-to-day variability exists, partly
due to clinical instability. Longer follow-up
studies are now warranted to evaluate whether
and how frequent FENO measurements may be
used to improve asthma management.
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